newsfilter
← Latest News
Business Wire·

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027 ‑ EVO301 full